Page last updated: 2024-08-24

aromasil and Cardiovascular Diseases

aromasil has been researched along with Cardiovascular Diseases in 6 studies

Research

Studies (6)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	5 (83.33)	29.6817
2010's	1 (16.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chapman, JA; Elliott, C; Gelmon, KA; Goss, PE; Ingle, JN; Muss, HB; Pritchard, KI; Shepherd, LE; Whelan, TJ	1
Bachelot, T; Crétin, J; Debled, M; Delozier, T; Falandry, C; Freyer, G; Mauriac, L; Mille, D; Pujade-Lauraine, E; Romestaing, P; You, B	1
Esteva, FJ; Hortobagyi, GN	1
Carlini, P; Cognetti, F; Felici, A; Ferretti, G	1
Fabian, CJ	1
Perez, EA	1

Reviews

3 review(s) available for aromasil and Cardiovascular Diseases

Article	Year
Comparative assessment of lipid effects of endocrine therapy for breast cancer: implications for cardiovascular disease prevention in postmenopausal women. Breast (Edinburgh, Scotland), 2006, Volume: 15, Issue:3 Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Estradiol; Female; Fulvestrant; Hormone Replacement Therapy; Humans; Lipids; Middle Aged; Nitriles; Osteoporosis, Postmenopausal; Risk Factors; Tamoxifen; Triazoles; Triglycerides	2006
The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer. International journal of clinical practice, 2007, Volume: 61, Issue:12 Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Chemotherapy, Adjuvant; Drug Resistance; Female; Humans; Letrozole; Musculoskeletal Diseases; Nitriles; Postmenopause; Premenopause; Tamoxifen; Thromboembolism; Triazoles	2007
Safety of aromatase inhibitors in the adjuvant setting. Breast cancer research and treatment, 2007, Volume: 105 Suppl 1 Topics: Anastrozole; Androstadienes; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Causality; Chemotherapy, Adjuvant; Comorbidity; Estrogen Receptor Modulators; Female; Hot Flashes; Humans; Incidence; Letrozole; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Neoplasms, Second Primary; Nitriles; Osteoporosis; Rats; Survival Analysis; Tamoxifen; Triazoles	2007

Trials

2 trial(s) available for aromasil and Cardiovascular Diseases

Article	Year
Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27. Breast cancer research and treatment, 2016, Volume: 156, Issue:2 Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Cause of Death; Chemotherapy, Adjuvant; Comorbidity; Female; Humans; Middle Aged; Nitriles; Postmenopause; Survival Analysis; Treatment Outcome; Triazoles	2016
Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study. Breast cancer research and treatment, 2009, Volume: 116, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Anti-Inflammatory Agents, Non-Steroidal; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Celecoxib; Chemotherapy, Adjuvant; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasms, Hormone-Dependent; Placebos; Postmenopause; Prognosis; Pyrazoles; Soft Tissue Neoplasms; Sulfonamides; Survival Rate; Treatment Outcome	2009

Article

Year

Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27.

Breast cancer research and treatment, 2016, Volume: 156, Issue:2

Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Cause of Death; Chemotherapy, Adjuvant; Comorbidity; Female; Humans; Middle Aged; Nitriles; Postmenopause; Survival Analysis; Treatment Outcome; Triazoles

2016

Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study.

Breast cancer research and treatment, 2009, Volume: 116, Issue:3

Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Anti-Inflammatory Agents, Non-Steroidal; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Celecoxib; Chemotherapy, Adjuvant; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasms, Hormone-Dependent; Placebos; Postmenopause; Prognosis; Pyrazoles; Soft Tissue Neoplasms; Sulfonamides; Survival Rate; Treatment Outcome

2009

Other Studies

1 other study(ies) available for aromasil and Cardiovascular Diseases

Article	Year
Exemestane or tamoxifen? Lancet (London, England), 2007, May-12, Volume: 369, Issue:9573 Topics: Androstadienes; Aromatase Inhibitors; Cardiovascular Diseases; Follow-Up Studies; Humans; Selective Estrogen Receptor Modulators; Tamoxifen	2007